Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma
1 other identifier
observational
15
1 country
1
Brief Summary
Non-invasive measurements of cardiac output (CO), systemic vascular resistance (SVR), corrected aortic flow time (FTc) and stroke volume (SV) are useful parameters during laparoscopic resection of pheochromocytoma (adrenalectomy) to document the intraoperative changes in volume status and to estimate the volume depletion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2011
CompletedFirst Submitted
Initial submission to the registry
August 24, 2011
CompletedFirst Posted
Study publicly available on registry
August 30, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2013
CompletedFebruary 13, 2014
February 1, 2014
1.9 years
August 24, 2011
February 12, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
Cardiac output (CO)
measured using esophageal doppler
parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours
Systemic vascular resistance (SVR)
measured using esophageal doppler
parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours
Stroke volume (SV)
measured using esophageal doppler
parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours
Corrected aortic flow time(FTc)
measured using esophageal doppler
parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours
Central venous pressure
Measured using esophageal doppler
parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours
Heart rate
parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours
Arterial blood pressure
systolic, diastolic, mean; continuous invasive measurement
parameter will be measured continously for the duration of adrenalectomy, an expected average of 3 hours
Secondary Outcomes (4)
Changes in serum Concentration: Epinephrine
7 timepoints during anesthesia (Administration of rocuronium, intubation, cut, intraabdominal air insufflation, ligature of v. suprarenalis, tumor exstirpation, end of operation)
Changes in serum concentration: Norepinephrine
7 timepoints during anesthesia (Administration of rocuronium, intubation, cut, intraabdominal air insufflation, ligature of v. suprarenalis, tumor exstirpation, end of operation)
Changes in serum concentration: Dopamin
7 timepoints during anesthesia (Administration of rocuronium, intubation, cut, intraabdominal air insufflation, ligature of v. suprarenalis, tumor exstirpation, end of operation)
Changes in plasma concentration: Metanephrines
7 timepoints during anesthesia (Administration of rocuronium, intubation, cut, intraabdominal air insufflation, ligature of v. suprarenalis, tumor exstirpation, end of operation)
Study Arms (2)
Pheochromocytoma Group
Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
Control group
Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
Eligibility Criteria
Patients suffering from pheochromocytoma will be recruited by the Department of Surgery, Medical University of Vienna
You may qualify if:
- Planned laparoscopic adrenalectomy for pheochromocytoma (Biochemical confirmed adrenal and extraadrenal pheochromocytoma)
- Planned laparoscopic adrenalectomy for hormonally inactive adrenal tumor
You may not qualify if:
- Risk of esophageal bleeding or perforation exists (i.e., liver disease with portal hypertension and/or esophageal varicoses, other esophageal anomalies).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical University of Vienna
Vienna, 1050, Austria
Related Publications (1)
Niederle MB, Fleischmann E, Kabon B, Niederle B. The determination of real fluid requirements in laparoscopic resection of pheochromocytoma using minimally invasive hemodynamic monitoring: a prospectively designed trial. Surg Endosc. 2020 Jan;34(1):368-376. doi: 10.1007/s00464-019-06777-z. Epub 2019 Apr 11.
PMID: 30976898DERIVED
Biospecimen
whole blood, serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Martin B Niederle, MD, DMedSc
Medical University of Vienna
- STUDY CHAIR
Edith Fleischmann, Prof, MD
Medical University of Vienna
- STUDY CHAIR
Bruno Niederle, Prof, MD
Medical University of Vienna
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, DMedSc
Study Record Dates
First Submitted
August 24, 2011
First Posted
August 30, 2011
Study Start
August 1, 2011
Primary Completion
July 1, 2013
Study Completion
July 1, 2013
Last Updated
February 13, 2014
Record last verified: 2014-02